Core Insights - The top three companies by stockholding ratio in the Hong Kong Stock Connect are China Telecom (71.90%), GCL-Poly Energy (69.96%), and Da Zhong Public Utilities (68.75%) [1][2] - The companies with the largest increase in stockholding over the last five trading days include SMIC (+1.092 billion), China Merchants Bank (+1.052 billion), and Hong Kong Exchanges and Clearing (+790 million) [1][2] - The companies with the largest decrease in stockholding over the last five trading days include China Mobile (-3.216 billion), Tencent Holdings (-1.107 billion), and the Tracker Fund of Hong Kong (-465 million) [1][2] Stockholding Ratios - China Telecom (00728) holds 99.79 million shares with a stockholding ratio of 71.90% [2] - GCL-Poly Energy (01330) holds 28.3 million shares with a stockholding ratio of 69.96% [2] - Da Zhong Public Utilities (01635) holds 36.7 million shares with a stockholding ratio of 68.75% [2] - Other notable companies in the top 20 include China Shenhua (66.39%) and China Merchants Energy (64.43%) [2] Recent Trading Activity - The top three companies with increased holdings in the last five trading days are: - SMIC (00981): +1.092 billion, +15.28 million shares [2][3] - China Merchants Bank (03968): +1.052 billion, +19.92 million shares [2][3] - Hong Kong Exchanges and Clearing (00388): +790 million, +1.93 million shares [2][3] - The top three companies with decreased holdings in the last five trading days are: - China Mobile (00941): -3.216 billion, -39.36 million shares [2][3] - Tencent Holdings (00700): -1.107 billion, -1.84 million shares [2][3] - Tracker Fund of Hong Kong (02800): -465 million, -18.01 million shares [2][3]

Core Viewpoint - The innovative pharmaceutical sector is expected to perform well in 2026, driven by strong business development (BD) activities and supportive industrial policies, despite recent market adjustments [1][4]. Group 1: Market Performance - The Hong Kong innovative drug index has seen a year-to-date increase of nearly 70%, with individual stocks like Shuyou Shen and Sanofi Biopharma doubling in price [1][2]. - In the A-share market, stocks such as Shuyou Shen and Sanofi Biopharma have also experienced significant gains, with Shuyou Shen's price soaring nearly 7 times at one point [2]. - The Hong Kong stock market has welcomed over 20 pharmaceutical companies this year, with notable first-day performances, including a nearly 300% increase for Yinnuo Pharmaceutical [2][3]. Group 2: Business Development (BD) Trends - The number of BD projects in the Chinese innovative drug sector reached 166 by December 5, 2025, marking an increase of 54 projects from the previous year [4]. - The total amount of BD transactions has reached $141.97 billion, a growth of over 136.8% compared to 2024, with upfront payments totaling $6.3 billion, up by over 199% [4][5]. - Major deals include a $13 billion transaction between Qiguang Dekang and Biohaven, and a collaboration between Sanofi Biopharma and Pfizer worth up to $48 billion [4][5]. Group 3: Future Outlook - Analysts predict that the innovative drug sector will continue to thrive in 2026, with a shift in focus from quantity to value in BD transactions [7]. - The industry is expected to see a selection of high-quality companies emerge as leaders, supported by a stable policy environment and improved market confidence [7][8]. - The innovative drug sector is anticipated to remain a core focus within the pharmaceutical industry, with significant benefits expected for related sectors such as CXO [7][8].

Group 1: Core Insights - The report maintains a strong market rating for the pharmaceutical industry, indicating a clear upward trend driven by recovering demand and improved performance in the CXO sector [1][2] - The CXO sector has shown significant stock price increases, with some companies experiencing nearly 100% growth since the beginning of 2025, driven by the innovative drug market and a recovery in orders [3][6] Group 2: CXO Sector Analysis - The CXO sector's overall revenue increased by 11.8% year-on-year in the first three quarters of 2025, with a notable profit increase of 58.1% [13] - External demand for CXO services has rebounded, with significant order growth from leading CDMO companies, indicating a clear recovery trend [22][31] - Internal demand for CXO services has lagged behind external demand, but there are signs of strong growth in domestic innovative drug projects and increased investment in the domestic market [3][22] Group 3: Life Sciences Upstream - The life sciences upstream sector has seen a 37.7% increase in stock prices year-to-date, outperforming the pharmaceutical and biotechnology index by 18% [3] - Revenue for the upstream sector increased by 8.8% year-on-year in the first three quarters of 2025, with net profit rising by 27.7% [3] Group 4: Investment Recommendations - The report suggests a strategic investment focus on companies such as WuXi AppTec, WuXi Biologics, and Tigermed, while also highlighting more flexible investment options like Zhaoyan New Drug and Nossan [3]

Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]

Core Viewpoint - The stock price of Zhaoyan New Drug (603127.SH) surged due to the rebound in the market price of experimental monkeys, prompting major shareholder Zhou Zhiwen to announce a significant share reduction plan, potentially cashing out over 500 million yuan [1] Group 1: Shareholder Actions - Zhou Zhiwen plans to reduce his holdings by up to 14,980,000 shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital, within three months after the announcement [1] - Prior to the reduction, Zhou Zhiwen held 74,725,981 shares, accounting for 9.9704% of the company, with the couple's total holding at 32.274% [1] - Following the announcement of the share reduction, Zhaoyan New Drug's stock fell by 6.20% to a closing price of 34.80 yuan [1] Group 2: Company Overview - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, with a notable focus on experimental monkeys, which are critical for various research fields [2] - The price of experimental monkeys has fluctuated significantly, with the average market price rising from 13,800 yuan in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] Group 3: Financial Performance - In Q1 2024, Zhaoyan New Drug reported a revenue of 325 million yuan, a year-on-year decrease of 12.07%, and a net loss of 272 million yuan, attributed to a 284 million yuan loss from changes in the fair value of biological assets [3] - By the first three quarters of 2025, the company achieved a revenue of 985 million yuan, a year-on-year decrease of 26.23%, but turned a profit with a net income of 80.71 million yuan [3] - The stock price of Zhaoyan New Drug increased by over 120% throughout the year, reflecting a recovery in the market price of experimental monkeys [3] Group 4: Market Perception - Some market analysts argue that Zhaoyan New Drug primarily sells experimental services rather than monkeys, suggesting that monkey prices do not directly reflect the company's sustainable profitability [4] - Despite this, fluctuations in the value of experimental monkeys significantly impact the company's financial performance, leading to potential distortions in financial reporting [4]

证券之星消息，12月30日医疗服务板块较上一交易日下跌0.73%，昭衍新药领跌。当日上证指数报收于 3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920670 | 数字人 | 15.87 | 4.20% | 5.91万 | 9396.08万 | | 600568 | ST中珠 | 2.52 | 2.86% | 22.48万 | 5686.21万 | | 300347 | 泰格医药 | 56.63 | 1.27% | 9.14万 | 5.16亿 | | 688621 | 阳光诺和 | 64.18 | 1.20% | 1.74万 | 1.10亿 | | 688131 | 皓元医药 | 72.54 | 0.96% | 2.24万 | 1.62亿 | | 301096 | 百诚医药 | 57.75 | 0.70% | 3.10万 | 1.78亿 | | 300363 | 博腾股份 | 23.45 ...

走势上看，新华500指数（989001）30日早间低开后上行翻红，早盘指数窄幅震荡，午后指数持续走强，最终小幅收涨。指数盘中最高触及5175.47点，最低 触及5120.42点，成分股全天总成交额报6997亿元。 成分股方面，恒逸石化、三花智控、中国卫通、拓普集团等成分股涨幅居前；金风科技、永辉超市、迈为股份、昭衍新药等成分股跌幅靠前。 新华500指数由国家金融信息平台•新华财经发布，新华指数（北京）有限公司运营维护，指数度量A股主要大中市值股票价格水平。关于新华500指数的详 细信息，请参见新华财经客户端。 转自：新华财经 新华财经北京12月30日电（胡晨曦）新华500指数（989001）12月30日收盘涨0.25%，报5158.39点。 编辑：罗浩 ...

中国经济网北京12月30日讯 昭衍新药（603127）(603127.SH)昨晚发布关于股东减持股份计划公告。 截至公告披露日，公司实际控制人之一周志文持有公司股票74,725,981股，占公司总股本9.9704%，其持有的股份来 源于首发前限售股份及公司资本公积金转增股份等。 周志文拟自减持计划公告之日起15个交易日后的3个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不超 过14,980,000股,不超过其持有股份的20.0466%，不超过公司总股本的1.99873%。减持计划实施期间，公司若发生送 红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整。减持价格依据市场价格确定。 按照12月29日收盘价37.1元测算，周志文套现金额约合5.56亿元。 昭衍新药2024年年度报告显示，公司实际控制人是冯宇霞（女）、周志文（男）夫妇。 昭衍新药表示，本次减持计划是股东根据自身资金需要进行的减持，本次减持不会对公司治理结构及持续经营情况 产生重大影响。在减持期间内，股东将根据市场情况、公司股价及有关规则所允许的可交易窗口期间等因素选择是 否实施本计划，因此减持时间、减持价格、减持数量存在 ...

Group 1 - The Hong Kong stock market saw a decline in CRO (Contract Research Organization) concept stocks, with notable drops in several companies [1] - Zhaoyan New Drug fell over 7%, while Kanglong Chemical and King’s Ray dropped over 4% [1] - Kylin and Weiya Bio experienced declines of over 2% [1]

Group 1 - The Hang Seng Index rose by 0.44%, gaining 113 points to reach 25,749 points, while the Hang Seng Tech Index increased by 1.04% [1] - Six new stocks were listed on the Hong Kong Stock Exchange with mixed performance; for instance, 英矽智能 (03696) surged over 34%, 美联股份 (02671) rose by 30%, and 迅策 (03317) saw a slight decline of 0.08% [1] - Baidu Group-SW (09888) led blue-chip gains with a 6.8% increase, driven by its expansion into the UK with autonomous vehicles and the anticipated ramp-up of its self-developed AI chip, Kunlun [1] Group 2 - 力勤资源 (02245) saw a rise of over 6% due to disruptions in the nickel market from Indonesian policies, with its fire refining project expected to be fully operational by 2026 [2] - 迈富时 (02556) increased by over 10% as it collaborates with Baidu and other tech companies, marking a pivotal point for the AI Agent's widespread adoption [2] - 英诺赛科 (02577) rose by over 9%, with its gallium nitride products meeting critical demands across multiple sectors [2] - 中伟新材 (02579) gained nearly 7% after signing a strategic cooperation framework agreement with 欣旺达 to jointly develop new precursor materials for solid-state batteries [2] - 亚太卫星 (01045) increased by 5%, operating multiple satellites including Asia-Pacific 5C as a subsidiary of China Satellite Communications [2] - 同源康医药-B (02410) rose by over 2% as it initiated Phase I/II clinical trials for TYK-01054 capsules, targeting advanced solid tumors [2] Group 3 - 昭衍新药 (06127) experienced a decline of over 6% as its controlling shareholder plans to reduce holdings by up to 14.98 million A-shares [3]